XML 30 R19.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Business Segments and Geographic Information | 6 Months Ended
--- | ---
Mar. 31, 2018
Segment Reporting [Abstract] |
Business Segments and Geographic Information | Business Segments and Geographic Information The Company has five reportable segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical and Skeletal Health. Certain reportable segments represent an aggregation of operating units within each segment. The Company measures and evaluates its reportable segments based on segment revenues and operating income adjusted to exclude the effect of non-cash charges, such as intangible asset amortization expense, intangible asset and goodwill impairment charges, acquisition related fair value adjustments and integration expenses, restructuring, divestiture and facility consolidation charges and other one-time or unusual items. Identifiable assets for the five principal operating segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company fully allocates depreciation expense to its five reportable segments. The Company has presented all other identifiable assets as corporate assets. There were no inter-segment revenues during the three and six months ended March 31, 2018 and April 1, 2017. Segment information is as follows:
| Three Months Ended |  | Six Months Ended
| March 31, 2018 |  | April 1, 2017 |  | March 31, 2018 |  | April 1, 2017
Total revenues: |  |  |  |  |  |  |
Diagnostics | $ | 279.7 |  |  | $ | 296.0 |  |  | $ | 564.3 |  |  | $ | 621.3 |
Breast Health | 300.1 |  |  | 280.5 |  |  | 588.1 |  |  | 553.8 |
Medical Aesthetics | 85.5 |  |  | 16.0 |  |  | 176.8 |  |  | 16.0 |
GYN Surgical | 99.4 |  |  | 101.1 |  |  | 206.9 |  |  | 215.9 |
Skeletal Health | 24.6 |  |  | 21.8 |  |  | 44.3 |  |  | 42.8 |
| $ | 789.3 |  |  | $ | 715.4 |  |  | $ | 1,580.4 |  |  | $ | 1,449.8 |
Income (loss) from operations: |  |  |  |  |  |  |
Diagnostics | $ | 34.2 |  |  | $ | 929.7 |  |  | $ | 70.7 |  |  | $ | 970.9 |
Breast Health | 101.5 |  |  | 92.7 |  |  | 191.2 |  |  | 177.9 |
Medical Aesthetics | (760.1 | ) |  | (24.5 | ) |  | (783.1 | ) |  | (24.5 | )
GYN Surgical | 17.9 |  |  | 1.8 |  |  | 48.2 |  |  | 27.2 |
Skeletal Health | 2.3 |  |  | 0.1 |  |  | 2.9 |  |  | (5.7 | )
| $ | (604.2 | ) |  | $ | 999.8 |  |  | $ | (470.1 | ) |  | $ | 1,145.8 |
Depreciation and amortization: |  |  |  |  |  |  |
Diagnostics | $ | 64.1 |  |  | $ | 64.4 |  |  | $ | 128.8 |  |  | $ | 149.3 |
Breast Health | 5.5 |  |  | 4.6 |  |  | 10.4 |  |  | 9.7 |
Medical Aesthetics | 27.0 |  |  | 2.5 |  |  | 55.5 |  |  | 2.5 |
GYN Surgical | 22.8 |  |  | 23.4 |  |  | 45.7 |  |  | 48.5 |
Skeletal Health | 0.1 |  |  | 0.2 |  |  | 0.3 |  |  | 0.4 |
| $ | 119.5 |  |  | $ | 95.1 |  |  | $ | 240.7 |  |  | $ | 210.4 |
Capital expenditures: |  |  |  |  |  |  |
Diagnostics | $ | 14.0 |  |  | $ | 11.5 |  |  | $ | 25.9 |  |  | $ | 21.8 |
Breast Health | 3.8 |  |  | 1.8 |  |  | 7.3 |  |  | 4.0 |
Medical Aesthetics | 3.5 |  |  | 0.4 |  |  | 5.1 |  |  | 0.4 |
GYN Surgical | 3.3 |  |  | 3.3 |  |  | 5.7 |  |  | 7.4 |
Skeletal Health | 0.1 |  |  | 0.1 |  |  | 0.8 |  |  | 0.4 |
Corporate | 2.3 |  |  | 8.0 |  |  | 4.0 |  |  | 15.8 |
| $ | 27.0 |  |  | $ | 25.1 |  |  | $ | 48.8 |  |  | $ | 49.8 |
| March 31, 2018 |  | September 30, 2017
Identifiable assets: |  |  |
Diagnostics | $ | 2,548.2 |  |  | $ | 2,621.6 |
Breast Health | 854.9 |  |  | 824.0 |
Medical Aesthetics | 967.2 |  |  | 1,751.2 |
GYN Surgical | 1,457.7 |  |  | 1,494.6 |
Skeletal Health | 26.1 |  |  | 25.5 |
Corporate | 1,380.3 |  |  | 1,262.7 |
| $ | 7,234.4 |  |  | $ | 7,979.6 |
The Company had no customers that represented greater than 10% of consolidated revenues during the three and six months ended March 31, 2018 and April 1, 2017. The Company operates in the following major geographic areas as noted in the below chart. Revenue data is based upon customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The Company’s sales in Europe are predominantly derived from France, Germany and the United Kingdom. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “Rest of World” designation includes Canada, Latin America and the Middle East. Revenues by geography as a percentage of total revenues were as follows:
| Three Months Ended |  | Six Months Ended
| March 31, 2018 |  | April 1, 2017 |  | March 31, 2018 |  | April 1, 2017
United States | 74.5 | % |  | 79.7 | % |  | 75.0 | % |  | 78.9 | %
Europe | 12.6 | % |  | 9.7 | % |  | 12.0 | % |  | 10.1 | %
Asia-Pacific | 7.9 | % |  | 6.5 | % |  | 8.3 | % |  | 7.4 | %
Rest of World | 5.0 | % |  | 4.1 | % |  | 4.7 | % |  | 3.6 | %
| 100.0 | % |  | 100.0 | % |  | 100.0 | % |  | 100.0 | %

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration